Edenred Stock: Marked Rebound Despite Regulatory Threat in Brazil
Edenred's stock is up nearly 3% this Thursday, reaching 18.90 euros, following the release of its 2025 annual results earlier this week. This increase comes amidst a challenging backdrop, as a Brazilian court ruling against the meal voucher market emerged the day before.
Significant Judicial Decision in Brazil
Today's upward momentum should not overshadow a major event that occurred yesterday. The president of the Brazilian federal court confirmed the applicability of the presidential decree of November 12, 2025, concerning the Worker's Food Program (PAT). This decision overturns the temporary suspension that Edenred and eight other issuers had benefited from since January 20, 2026, obtained following a class action lawsuit. The Brazilian government had contested this stay, and the court ruled in its favor. The French group, for whom Brazil is one of the main markets outside Europe, must now comply with the new regulations in the coming days. This decree more strictly regulates the issuance and use of meal and food vouchers in the country. The precise financial impact of this measure has not yet been quantified by the company, but Brazil has historically been a significant growth driver for Edenred's Employee Benefits activity.
Medium-Term Fragility Despite Recent Gains
Despite a rebound of 6.42% over the last seven days, Edenred's trajectory remains weakened in the medium term: the stock has declined by 37.33% over the year. The current price, at 18.90 euros, is approaching the resistance threshold of 19.00 euros. A sustained crossing of this level could alter the graphical configuration, as the stock is currently above its 50-day moving average (18.16 euros), indicating a short-term trend improvement. However, the 200-day moving average, positioned at 22.28 euros, remains far from the current price, reflecting the persistent degradation of the long-term trend. The RSI, an indicator measuring the speed and magnitude of price changes, stands at 56, a neutral zone that signals neither overbuying nor overselling. The publication of the 2025 annual results on February 24 and the upcoming first-quarter revenue deadline, expected on April 23, will be the next catalysts likely to influence the stock.
